Literature DB >> 26942062

Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions.

Marion Thibaudin1, Marie Chaix2, Romain Boidot3, Frédérique Végran3, Valentin Derangère4, Emeric Limagne4, Hélène Berger4, Sylvain Ladoire3, Lionel Apetoh5, François Ghiringhelli5.   

Abstract

Th17 cells contribute to the development of some autoimmune and allergic diseases by driving tissue inflammation. However, the function of Th17 cells during cancer progression remains controversial. Here, we show that human memory CD25high Th17 cells suppress T cell immunity in breast cancer. Ectonucleotidase-expressing Th17 cells accumulated in breast cancer tumors and suppressed CD4+ and CD8+ T cell activation. These cells expressed both Rorγt and Foxp3 genes and secreted Th17 related cytokines. We further found that CD39 ectonucleotisase expression on tumor-infiltrating Th17 cells was driven by TGF-βand IL-6. Finally, immunohistochemical analysis of localized breast cancer revealed that high-tumor infiltration by IL-17+ cells was associated with a poor clinical outcome and impeded the favorable effect of high CD8+ infiltration. Altogether, these findings suggest that intratumoral Th17 cells compromise anticancer immune responses in breast cancer patients.

Entities:  

Keywords:  Th17; breast cancer; ectonucleotidase; prognosis

Year:  2015        PMID: 26942062      PMCID: PMC4760277          DOI: 10.1080/2162402X.2015.1055444

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  26 in total

Review 1.  IL-17 and Th17 Cells.

Authors:  Thomas Korn; Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

2.  Enzyme-coupled assays for simultaneous detection of nanomolar ATP, ADP, AMP, adenosine, inosine and pyrophosphate concentrations in extracellular fluids.

Authors:  Mikko Helenius; Sirpa Jalkanen; Gennady Yegutkin
Journal:  Biochim Biophys Acta       Date:  2012-10

3.  Adenosine production by human B cells and B cell-mediated suppression of activated T cells.

Authors:  Zenichiro Saze; Patrick J Schuler; Chang-Sook Hong; Dongmei Cheng; Edwin K Jackson; Theresa L Whiteside
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

4.  Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells.

Authors:  Eva V Acosta-Rodriguez; Laura Rivino; Jens Geginat; David Jarrossay; Marco Gattorno; Antonio Lanzavecchia; Federica Sallusto; Giorgio Napolitani
Journal:  Nat Immunol       Date:  2007-05-07       Impact factor: 25.606

5.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.

Authors:  Mélanie Bruchard; Grégoire Mignot; Valentin Derangère; Fanny Chalmin; Angélique Chevriaux; Frédérique Végran; Wilfrid Boireau; Benoit Simon; Bernhard Ryffel; Jean Louis Connat; Jean Kanellopoulos; François Martin; Cédric Rébé; Lionel Apetoh; François Ghiringhelli
Journal:  Nat Med       Date:  2012-12-02       Impact factor: 53.440

6.  Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.

Authors:  P J Schuler; Z Saze; C-S Hong; L Muller; D G Gillespie; D Cheng; M Harasymczuk; M Mandapathil; S Lang; E K Jackson; T L Whiteside
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

7.  Human T cells that are able to produce IL-17 express the chemokine receptor CCR6.

Authors:  Satya P Singh; Hongwei H Zhang; John F Foley; Michael N Hedrick; Joshua M Farber
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

Review 8.  The CC chemokine CCL20 and its receptor CCR6.

Authors:  Evemie Schutyser; Sofie Struyf; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2003-10       Impact factor: 7.638

9.  Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

Authors:  Ilona Kryczek; Mousumi Banerjee; Pui Cheng; Linhua Vatan; Wojciech Szeliga; Shuang Wei; Emina Huang; Emily Finlayson; Diane Simeone; Theodore H Welling; Alfred Chang; George Coukos; Rebecca Liu; Weiping Zou
Journal:  Blood       Date:  2009-05-21       Impact factor: 22.113

10.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks.

Authors:  Gabriela Bindea; Bernhard Mlecnik; Hubert Hackl; Pornpimol Charoentong; Marie Tosolini; Amos Kirilovsky; Wolf-Herman Fridman; Franck Pagès; Zlatko Trajanoski; Jérôme Galon
Journal:  Bioinformatics       Date:  2009-02-23       Impact factor: 6.937

View more
  22 in total

1.  [Th1/Th2 and Treg/Th17 cell balance in peripheral blood of patients with ovarian cancer].

Authors:  Li-Hua Wang; Liang-Liang Wang; Jing Zhang; Pei Zhang; Sheng-Ze Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-08-20

2.  Immune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Authors:  Rachid Madkouri; Coureche Guillaume Kaderbhai; Aurélie Bertaut; Caroline Truntzer; Julie Vincent; Marie Hélene Aubriot-Lorton; Walid Farah; Emeric Limagne; Sylvain Ladoire; Romain Boidot; Valentin Derangère; François Ghiringhelli
Journal:  Oncoimmunology       Date:  2017-04-28       Impact factor: 8.110

Review 3.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

4.  The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

Authors:  Sènan M d'Almeida; Gilles Kauffenstein; Charlotte Roy; Laetitia Basset; Loukas Papargyris; Daniel Henrion; Véronique Catros; Norbert Ifrah; Philippe Descamps; Anne Croue; Pascale Jeannin; Marc Grégoire; Yves Delneste; Julie Tabiasco
Journal:  Oncoimmunology       Date:  2016-04-28       Impact factor: 8.110

Review 5.  Immune microenvironment in different molecular subtypes of ductal breast carcinoma.

Authors:  Mona Sadeghalvad; Hamid-Reza Mohammadi-Motlagh; Nima Rezaei
Journal:  Breast Cancer Res Treat       Date:  2020-10-03       Impact factor: 4.872

Review 6.  Targeting ectonucleotidases to treat inflammation and halt cancer development in the gut.

Authors:  Maria Serena Longhi; Lili Feng; Simon C Robson
Journal:  Biochem Pharmacol       Date:  2021-01-15       Impact factor: 5.858

Review 7.  Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.

Authors:  Paola de Andrade Mello; Robson Coutinho-Silva; Luiz Eduardo Baggio Savio
Journal:  Front Immunol       Date:  2017-11-14       Impact factor: 7.561

8.  Infiltration of γ⁢δ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer.

Authors:  Roni Allaoui; Catharina Hagerling; Eva Desmond; Carl-Fredrik Warfvinge; Karin Jirström; Karin Leandersson
Journal:  Cancer Biomark       Date:  2017-12-08       Impact factor: 4.388

9.  Role of IL-23 signaling in the progression of premalignant oral lesions to cancer.

Authors:  Blaine Caughron; Yi Yang; M Rita I Young
Journal:  PLoS One       Date:  2018-04-17       Impact factor: 3.240

10.  Th17 Cells in Protection from Tumor or Promotion of Tumor Progression.

Authors:  M Rita I Young
Journal:  J Clin Cell Immunol       Date:  2016-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.